Advances in Chronic Kidney Disease
Volume 12, Issue 3 , Pages 326-334 , July 2005

Chronic Pain in End-Stage Renal Disease

  • Sara N. Davison

      Affiliations

    • Corresponding Author InformationAddress correspondence to Sara N. Davison, MD, MHSc (bioethics), FRCP(C), Division of Nephrology and Immunology, University of Alberta, Edmonton, Alberta, Canada

References 

  1. Merskey H , Bogduk N . Classification of Chronic Pain . In: Seattle, WA: International Association for the Study of Pain Press; 1994;p. 210
  2. Davison SN . Pain in hemodialysis patients (Prevalence, etiology, severity, and management) . Am J Kidney Dis . 2003;42:1239–1247
  3. Fainsinger R , Davison SN , Brenneis C . A supportive care model for dialysis patients . Palliat Med . 2003;17:81–82
  4. Fortina F , Agllata S , Ragazzoni E , et al.   Chronic pain during dialysis (Pharmacologic therapy and its costs) . Minerva Urol Nefrol . 1999;51:85–87
  5. Cohen LM , Germain M , Poppel DM , et al.   Dialysis discontinuation and withdrawal of dialysis . Am J Kidney Dis . 2000;36:140–144
  6. Sanders SH . Chronic pain (conceptualization and epidemiology) . Ann Behav Med . 1985;7:3–5
  7. Von Korff M , Dworkin SF , Le Resche L , et al.   An epidemiologic comparison of pain complaints . Pain . 1988;32:173–183
  8. Kimmel PL , Emont SL , Newmann JM , et al.   ESRD patient quality of life (symptoms, spiritual beliefs, psychological factors, and ethnicity) . Am J Kidney Dis . 2003;42:713–721
  9. Davison SN . The impact of chronic pain on depression, sleep, and the desire to withdraw from dialysis in hemodialysis patients . J Pain Sympt Manage . 2005; (in press)
  10. Saunders C . The Management of Terminal Illness . London: Edward Arnold; 1967;
  11. Joishy SK . Palliative Medicine Secrets . Philadelphia, PA: Hanley & Belfus Inc; 1999; , pp 1–231
  12. Bailie GR , Mason NA , Bragg-Gresham JL , et al.   Analgesic prescription patterns among hemodialysis patients in the DOPPS (Potential for underprescription) . Kidney Int . 2004;65:2419–2425
  13. McQuay H , Moore A . An Evidence Based Resource for Pain Relief . Oxford: Oxford University Press; 1988;
  14. Zech DFJ , Ground S , Lynch J , et al.   Validation for World Health Organization Guidelines for cancer pain relief (A 10-year prospective study) . Pain . 1995;63:65–76
  15. Cleeland C , Gonin R , Hatfield AK , et al.   Pain and its treatment in outpatients with metastatic cancer . New Eng J Med . 1994;330:592–596
  16. Anderson KO , Mendoza TR , Valero V , et al.   Minority cancer patients and their providers (Pain management attitudes and practice) . Cancer . 2000;88:1929–1938
  17. Chauvin M , Sandouk P , Scherrmann JM , et al.   Morphine pharmacokinetics in renal failure . Anesthesiology . 1987;66:327–331
  18. Glare PA , Walsh TD , Pippenger CE . Normorphine, a neurotoxic metabolite? . Lancet . 1990;335:725–726
  19. Hagen NA , Foley KM , Cerbone DJ , et al.   Chronic nausea and morphine-6-glucuronide . J Pain Symptom Manage . 1991;6:125–128
  20. Pasternak GW , Bodnar RJ , Clark JA . Morphine-6-glucuronide, a potent Mu agonist . Life Sci . 1987;41:2845–2849
  21. Sear JW , Hand CW , Moore RA , et al.   Studies on morphine disposition (Influence of renal failure on kinetics of morphine and its metabolites) . Br J Anaesth . 1989;62:28–32
  22. Hanna MH , D’Costa F , Peat SJ , et al.   Morphine-6-glucuronide disposition in renal impairment . Br J Anaesth . 1993;70:511–514
  23. Bruera E , Sloan P , Mount B  Canadian Palliative Care Clinical Trials Group . A randomized, double-blind, double-dummy, crossover trial comparing the safety and efficacy of oral sustained-release hydromorphone with immediate-release hydromorphone in patients with cancer pain . J Clin Oncol . 1996;14:1713–1717
  24. Dunbar PJ , Chapman CR , Buckley FP , et al.   Clinical analgesic equivalence for morphine and hydromorphone with prolonged PCA . Pain . 1996;68:265–270
  25. Valner JJ , Steward JT , Kotzan JA , et al.   Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects . J Clin Pharmacol . 1981;21:152–156
  26. Quigley C . Hydromorphone for acute and chronic pain . Cochrane Database Syst Rev CD003447 . 2002;
  27. Sarhill N , Walsh D , Nelson KA . Hydromorphone (Pharmacology and clinical applications in cancer patients) . Supportive Care in Cancer . 2001;9:84–96
  28. Babul N , Darke AC , Hage N . Hydromorphone metabolite accumulation in renal failure . J Pain Symptom Manage . 1995;10:184–186
  29. Hagen N , Swanson R . Multifocal myoclonus and seizures in extremely high dose opioid administration . Proceedings of the American Academy of Neurology . 1993;
  30. Fainsinger R , Schoeller T , Boiskin M , et al.   Palliative care round (Cognitive failure and coma after renal failure in a patient receiving Captopril and hydromorphone) . J Palliat Care . 1993;9:53–55
  31. Lee MA , Leng ME , Tiernan EJ . Retrospective study of the use of hydromorphone in palliative care patients with normal and abnormal urea and creatinine . Palliat Med . 2001;15:26–34
  32. Hardman JG , Goodman Gilman A , Limbird LE . Goodman & Gilman’s The Pharmacological Basis of Therapeutics (ed 9) (CD ROM version) . New York, NY: McGraw Hill, Health Professionals Division; 1996;
  33. Davies AM , Inturrisi J . d-methadone blocks morphine tolerance and N-methyl-D-aspartate-induced hyperalgesia . J Pharmacol Exp Ther . 1999;289:1048–1053
  34. Hewitt DJ . The use of NMDA-receptor antagonists in the treatment of chronic pain . Clin J Pain . 2000;16:S73–S79
  35. Bruera E , Neumann CM . Role of methadone in the management of pain in cancer patients . Oncology . 1999;13:1275–1288
  36. Gourlay GK , Cherry DA , Cousins MJ . A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer pain . Pain . 1986;25:297–312
  37. Morrison JD , Loan WB , Dundee JW . Controlled comparison of the efficacy of fourteen preparations in the relief of post-operative pain . Br Med J . 1971;2:287–290
  38. Dole VP , Kreek MJ . Methadone plasma level (Sustained by a reservoir of drug) . Proc Natl Acad Sci U S A . 1973;70:10–15
  39. Pohland A , Boaz HE , Sullivan HR . Synthesis and identification of metabolites resulting from the biotransformation of d,1-methadone in man and in the rat . J Med Chem . 1971;14:194–197
  40. Furlan V , Hafi A , Dessalles MC , et al.   Methadone is poorly removed by hemodialysis . Nephrol Dial Transplant . 1999;14:254–255
  41. Kreek MJ , Schecter AJ , Gutjahr CL , et al.   Methadone use in patients with chronic renal disease . Drug Alcohol Dependencies . 1980;5:197–205
  42. Mather LE . Clinical pharmacokinetics of fentanyl and its newer derivatives . Clin Pharmakinet . 1983;8:422–446
  43. Paix A , Coleman A , Lees J , et al.   Subcutaneous fentanyl and sufentanil infusion substitution for morphine intolerance in cancer management . Pain . 1995;63:263–269
  44. Zech DFJ , Grond SUA , Lynch J , et al.   Transdermal fentanyl and initial dose-finding with patient-controlled analgesia in cancer pain (A pilot study with 20 terminally ill cancer patients) . Pain . 1992;50:293–301
  45. McClain DA , Hug CC . Intravenous fentanyl kinetics . Clin Pharmacol Ther . 1980;28:106–114
  46. Bower S . Plasma protein binding of fentanyl (The effect of hyperlipoproteinemia and chronic renal failure) . J Pharm Pharmacol . 1982;34:102–106
  47. Koehntop DE , Rodman JH . Fentanyl pharmacokinetics in patients undergoing renal transplantation . Pharmacotherapy . 1997;17:745–752
  48. Corall IM , Moore AR , Strunin L . Plasma concentrations of fentanyl in normal surgical patients and those with severe renal and hepatic disease . Br J Anaesth . 1980;52:101
  49. Koren G , Crean PGGV , Klein J , et al.   Pharmacokinetics of fentanyl in children with renal disease . Res Commun Chem Pathol Pharmacol . 1984;46:371–379
  50. Mercandante S , Caligara M , Sapio M , et al.   Subcutaneous fentanyl infusion in a patient with bowel obstruction and renal failure . J Pain Symptom Manage . 1997;13:241–244
  51. Serlin RC , Mendoza TR , Nakamura Y , et al.   When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function . Pain . 1995;61:277–284
  52. Kurella M , Bennett WM , Chertow GM . Analgesia in patients with ESRD (A review of available evidence) . Am J Kidney Dis . 2003;42:217–228
  53. Ferro CJ , Davison SN , Chambers EJ . Management of pain in renal failure . In:  Chambers EJ ,  Germain M ,  Brown E editor. Supportive Care for the Renal Patient . Oxford, UK: Oxford University Press; 2004;p. 105–142
  54. Henrich WL , Agodoa LE , Barrett B , et al.   Analgesics and the kidney (Summary and recommendations to the Scientific Advisory Board of the National Kidney Foundation from an Ad Hoc Committee of the National Kidney Foundation) . Am J Kidney Dis . 1996;27:162–165
  55. Cohen LM , Reiter GS , Poppel DM , et al.   Palliative Care for Non-Cancer Patients (Renal Palliative Care) . In: New York, NY: Oxford University Press; 2001;p. 103–113

PII: S1548-5595(05)00074-1

doi: 10.1016/j.ackd.2005.03.008

Advances in Chronic Kidney Disease
Volume 12, Issue 3 , Pages 326-334 , July 2005

Article Tools

* Image Usage & Resolution